SBIR/STTR Award attributes
AbstractIn this project, we present EyeMark, a system with advanced longitudinal image anal- ysis tools for automated computation of biomarkers for diabetic retinopathy (DR) using retinal fundus images. Specifically, we have developed tools for computation of microan- eurysm (MA) appearance and disappearance rates (jointly known as turnover rates) for use as a biomarker in quantifying DR progression risk along with longitudinal analysis of other DR lesions. The availability of a reliable image-based biomarker will have high pos- itive influence on various aspects of DR care, including screening, monitoring progres- sion, drug discovery and clinical research.Measuring MA turnover and longitudinal analysis of DR lesions involves two labor in- tensive steps: careful alignment of current and baseline images, and marking of individual lesions. This process is very time consuming and prone to error, if done entirely by human graders. The primary goal of this project is to overcome these limitations by automating both the steps involved in longitudinal analysis: accurate image registration, and lesion identification.We have designed and developed a prototype tool that robustly registers longitudinal images (even with multiple lesion changes) and effectively detects and localizes DR le- sions. This fully automated tool can work on the cloud to produces results in near constant time (for large datasets), and also provide intuitive visualization tools for clinicians to more effectively monitor DR progression. This commercialization readiness pilot (CRP) project is intended to develop a regulatory strategy and a market access plan for EyeMark to enable its introduction in the US market and foster commercial success.Narrative The proposed tool, EyeMark, will greatly enhance the clinical care available to diabetic retinopathy (DR) patients by providing an automated tool for computation of an image- based, reliable, DR biomarker in a non-invasive manner. This will enable identification of patients who are at higher risk to progress to severe retinopathy, thus helping prevent vision loss in such patients by timely intervention. Early identification is especially important in face of long backlog of diabetic patients waiting for an eye examination, and the fact that 90% of vision loss can be saved by early identification. The availability of an effective biomarker will also positively influence the drug discovery process by facilitating early and reliable determination of biological efficacy of potential new therapies.
